Connection
Michael Verneris to Immunotherapy, Adoptive
This is a "connection" page, showing publications Michael Verneris has written about Immunotherapy, Adoptive.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.050 |
|
|
|
-
Bair SM, Pinto N, Roth A, Verneris M, Haverkos B, Nicklawsky A, Ohm A, Jordan K, Murphy LA, Marians R, Mallo R, Orentas R, Adams C, Kamdar M, Fry T. Feasibility and Safety of a Novel CD19-Directed CAR T-Cell Therapy in Patients with R/R B-Cell Non-Hodgkin Lymphoma. Transplant Cell Ther. 2026 Oct; 32(10):1268.e1-1268.e12.
Score: 0.178
-
Naik S, Aplenc R, Baumeister SHC, Becilli M, Bhagwat AS, Bonifant CL, Budde LE, Chien CD, Curran KJ, Daniyan AF, Dreyzin A, Gardner RA, Ghorashian S, Gottschalk S, Hill LC, Kohler ME, Lamble A, Locatelli F, Mamonkin M, Omer B, Park JH, Quintarelli C, Rambaldi B, Richards RM, Sallman DA, Sauer T, Shah NN, Subklewe M, Summers C, Tasian SK, Taylor N, Tettamanti S, Verneris MR, Velasquez MP, Gill SI. International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML. Blood Adv. 2025 Dec 09; 9(23):6047-6058.
Score: 0.173
-
Deimundo Roura C, Amrolia P, Ansari M, Bader P, Balduzzi A, Buechner J, Hsieh EM, Myers RM, Ottaviano G, Peters C, Rouce RH, Shah NN, Verneris MR, Kalwak K, Pulsipher MA. Opportunities and Challenges With CAR T-cell Treatment of Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia: Review and Recommendations From the Westhafen Intercontinental Group. Transplant Cell Ther. 2026 Mar; 32(3):261-276.
Score: 0.171
-
Naik S, Selukar S, Talleur AC, Deshpande S, Llaurador Caraballo G, Fabrizio VA, Rouce RH, Zeng XL, Vatsayan A, Rossoff J, Pacenta HL, John S, Phillips CL, Talano JA, Moskop A, Verneris MR, Myers GD, Hall E, Karras N, Bonifant CL, Qayed M, Bakinowski E, Keating AK, Baumeister SHC, Tomilson E, Hermiston ML, Satwani P, Krupski C, Chinnabhandar V, Stefanski HE, Egeler E, Curran KJ, Laetsch TW, Mackall CL, Prabhu S, Nguyen KP, Baggott C, Schultz LM, McNerney KO. Characterization and prediction of prolonged severe neutropenia in pediatric patients receiving tisagenlecleucel. Blood Adv. 2025 Oct 14; 9(19):5070-5084.
Score: 0.171
-
Lake JA, Woods E, Hoffmeyer E, Schaller KL, Cruz-Cruz J, Fernandez J, Tufa D, Kooiman B, Hall SC, Jones D, Hayashi M, Verneris MR. Directing B7-H3 chimeric antigen receptor T cell homing through IL-8 induces potent antitumor activity against pediatric sarcoma. J Immunother Cancer. 2024 Jul 23; 12(7).
Score: 0.157
-
Hsieh EM, Myers RM, Yates B, Annesley C, John S, Taraseviciute A, Steinberg SM, Sheppard J, Chung P, Chen L, Lee DW, DiNofia A, Grupp SA, Verneris MR, Laetsch TW, Bhojwani D, Brown PA, Pulsipher MA, Rheingold SR, Gardner RA, Gore L, Shah NN, Lamble AJ. Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy. Blood Adv. 2022 09 13; 6(17):5222-5226.
Score: 0.138
-
Fabrizio VA, Boelens JJ, Mauguen A, Baggott C, Prabhu S, Egeler E, Mavroukakis S, Pacenta H, Phillips CL, Rossoff J, Stefanski HE, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Chinnabhandar V, Kunicki M, Goksenin AY, Mackall CL, Laetsch TW, Schultz LM, Curran KJ. Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. Blood Adv. 2022 04 12; 6(7):1961-1968.
Score: 0.134
-
Myers GD, Verneris MR, Goy A, Maziarz RT. Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia. J Immunother Cancer. 2021 04; 9(4).
Score: 0.125
-
Davis ZB, Felices M, Verneris MR, Miller JS. Natural Killer Cell Adoptive Transfer Therapy: Exploiting the First Line of Defense Against Cancer. Cancer J. 2015 Nov-Dec; 21(6):486-91.
Score: 0.086
-
Miller JS, Rooney CM, Curtsinger J, McElmurry R, McCullar V, Verneris MR, Lapteva N, McKenna D, Wagner JE, Blazar BR, Tolar J. Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy. Biol Blood Marrow Transplant. 2014 Aug; 20(8):1252-7.
Score: 0.077
-
Knorr DA, Bachanova V, Verneris MR, Miller JS. Clinical utility of natural killer cells in cancer therapy and transplantation. Semin Immunol. 2014 Apr; 26(2):161-72.
Score: 0.076
-
Gleason MK, Verneris MR, Todhunter DA, Zhang B, McCullar V, Zhou SX, Panoskaltsis-Mortari A, Weiner LM, Vallera DA, Miller JS. Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production. Mol Cancer Ther. 2012 Dec; 11(12):2674-84.
Score: 0.069
-
Lee DA, Verneris MR, Campana D. Acquisition, preparation, and functional assessment of human NK cells for adoptive immunotherapy. Methods Mol Biol. 2010; 651:61-77.
Score: 0.057
-
Verneris MR, Miller JS. The phenotypic and functional characteristics of umbilical cord blood and peripheral blood natural killer cells. Br J Haematol. 2009 Oct; 147(2):185-91.
Score: 0.056
-
Lamble AJ, Myers RM, Taraseviciute A, John S, Yates B, Steinberg SM, Sheppard J, Kovach AE, Wood B, Borowitz MJ, Stetler-Stevenson M, Yuan CM, Pillai V, Foley T, Chung P, Chen L, Lee DW, Annesley C, DiNofia A, Grupp SA, Verneris MR, Gore L, Laetsch TW, Bhojwani D, Brown PA, Pulsipher MA, Rheingold SR, Gardner RA, Shah NN. Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells. Blood Adv. 2023 02 28; 7(4):575-585.
Score: 0.036
-
Edinger M, Cao YA, Verneris MR, Bachmann MH, Contag CH, Negrin RS. Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood. 2003 Jan 15; 101(2):640-8.
Score: 0.035
-
Schultz LM, Eaton A, Baggott C, Rossoff J, Prabhu S, Keating AK, Krupski C, Pacenta H, Philips CL, Talano JA, Moskop A, Baumeister SHC, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Wilcox R, Rabik CA, Fabrizio VA, Chinnabhandar V, Kunicki M, Mavroukakis S, Egeler E, Li Y, Mackall CL, Curran KJ, Verneris MR, Laetsch TW, Stefanski H. Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2023 01 10; 41(2):354-363.
Score: 0.034
-
Verneris MR, Baker J, Edinger M, Negrin RS. Studies of ex vivo activated and expanded CD8+ NK-T cells in humans and mice. J Clin Immunol. 2002 May; 22(3):131-6.
Score: 0.034
-
Fabrizio VA, Phillips CL, Lane A, Baggott C, Prabhu S, Egeler E, Mavroukakis S, Pacenta H, Rossoff J, Stefanski HE, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Chinnabhandar V, Kunicki M, Goksenin AY, Curran KJ, Mackall CL, Laetsch TW, Schultz LM. Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report. Blood Adv. 2022 01 25; 6(2):600-610.
Score: 0.033
-
Negrin RS, Edinger M, Verneris M, Cao YA, Bachmann M, Contag ChH. Visualization of tumor growth and response to NK-T cell based immunotherapy using bioluminescence. Ann Hematol. 2002; 81 Suppl 2:S44-5.
Score: 0.033
-
Schultz LM, Baggott C, Prabhu S, Pacenta HL, Phillips CL, Rossoff J, Stefanski HE, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Fabrizio VA, Rouce RH, Chinnabhandar V, Kunicki M, Barsan VV, Goksenin AY, Li Y, Mavroukakis S, Egeler E, Curran KJ, Mackall CL, Laetsch TW. Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report. J Clin Oncol. 2022 03 20; 40(9):945-955.
Score: 0.033
-
Rossoff J, Baggott C, Prabhu S, Pacenta H, Phillips CL, Stefanski H, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras N, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Fabrizio VA, Kunicki M, Chinnabhandar V, Goksenin AY, Curran KJ, Mackall CL, Laetsch TW, Schultz LM. Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia. Blood. 2021 11 25; 138(21):2138-2142.
Score: 0.033
-
Verneris MR, Ito M, Baker J, Arshi A, Negrin RS, Shizuru JA. Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma. Biol Blood Marrow Transplant. 2001; 7(10):532-42.
Score: 0.031
-
Orlando EJ, Han X, Tribouley C, Wood PA, Leary RJ, Riester M, Levine JE, Qayed M, Grupp SA, Boyer M, De Moerloose B, Nemecek ER, Bittencourt H, Hiramatsu H, Buechner J, Davies SM, Verneris MR, Nguyen K, Brogdon JL, Bitter H, Morrissey M, Pierog P, Pantano S, Engelman JA, Winckler W. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med. 2018 10; 24(10):1504-1506.
Score: 0.026
-
He F, Warlick E, Miller JS, MacMillan M, Verneris MR, Cao Q, Weisdorf D. Lymphodepleting chemotherapy with donor lymphocyte infusion post-allogeneic HCT for hematological malignancies is associated with severe, but therapy-responsive aGvHD. Bone Marrow Transplant. 2016 Aug; 51(8):1107-12.
Score: 0.022
-
Cichocki F, Verneris MR, Cooley S, Bachanova V, Brunstein CG, Blazar BR, Wagner J, Schlums H, Bryceson YT, Weisdorf DJ, Miller JS. The Past, Present, and Future of NK Cells in Hematopoietic Cell Transplantation and Adoptive Transfer. Curr Top Microbiol Immunol. 2016; 395:225-43.
Score: 0.022
-
Karimi M, Cao TM, Baker JA, Verneris MR, Soares L, Negrin RS. Silencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated CD8+ T cells and NK cells. J Immunol. 2005 Dec 15; 175(12):7819-28.
Score: 0.011
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|